Table 2.
Distribution of possible risk factors of the investigated cohort
| Risk factors | Preceding years n = 663 (%) |
Covid-19 year n = 298 (%) |
p-value |
|---|---|---|---|
| Wound healing disorders | 18 (2.7) | 6 (2.0) | |
| Smoker | 197 (29.7) | 83 (27.9) | |
| Alcohol (C2) consumption daily | 18 (2.7) | 10 (3.4) | |
| C2 occasionally | 33 (5.0) | 9 (3.0) | |
| C2 seldomly | 1 (0.2) | 0 (0) | |
| Drug history | 16 (2.4) | 2 (0.7) | |
| Pregnancy | 4 (0.6) | 2 (0.7) | |
| Age 0–3 years | 1 (0.2) | 1 (0.3) | 0.136** |
| Age 4–12 years | 25 (3.8) | 11 (3.7) | |
| Age 13–64 years | 495 (74.7) | 225 (75.5) | |
| Age 65–84 years | 127 (19.2) | 46 (15.4) | |
| ≥ 85 years of age | 15 (2.3) | 15 (5.1) | |
| ≥ 65 years of age | 142 (21.4) | 61 (20.5) | |
| Long-term carea | |||
| Long-term care nursing home | 20 (3.3) | 9 (3.2) | |
| Long-term care outpatient service | 4 (0.7) | 0 (0) | |
| BMI ≥ 40 kg/m2b | 4 (1.5) | 5 (3.2) | |
| Previous surgeryc | 274 (55.0) | 136 (65.1) | *0.015 |
| ≥ 5 drugs for medication | 92 (13.9) | 41 (13.8) | |
| Antiresorptive drugs total | 18 (2.8) | 9 (3.0) | |
| Current intake | 17 (2.6) | 8 (2.7) | |
| History of intake | 1 (0.2) | 1 (0.3) | |
| Glucocorticoids | 18 (2.7) | 12 (4.0) | |
| Immune suppressive therapy | 34 (5.1) | 17 (5.7) | |
| ACE-I, ARB | 93 (14.0) | 46 (15.4) | |
| NSAID | 147 (22.2) | 61 (20.5) | |
| History of radiation therapy | 14 (2.1) | 5 (1.7) | |
Preceding years = control group: 2018–2020
Covid-19 year = test group: 2020–2021
Abbreviations: ACE-I Angiotensin-converting enzyme (ACE) inhibitors, ARB Angiotensin receptor blockers, NSAID Non-steroidal anti-inflammatory drugs
an = 876 (85 non-registered cases)
bn = 707 (254 non-registered cases)
cn = 461 (545 non-registered cases)
*Fisher’s Exact Test
**Chi2-Test